Development of 2 unique vaccines with multiple applications
G P Talwar
Talwar Research Foundation, India
: J Clin Exp Oncol
We developed an immunoprophylactic cum immunotherapeutic Vaccine against Leprosy. It is based on saprophytic cultivable mycobacteria, which is now sequenced and named as Mycobacterium indicus pranii (MIP). MIP has been launched in 36 Districts of high endemicity in May 2017 by the Govt. of India for eradication of leprosy. Besides leprosy, MIP is being used for treatment of Category II Difficult to treat patients suffering from tuberculosis. It is a potent invigorator of immune responses. It heals ugly ano-genital warts, and is being used for treatment of some cancers. MIP is approved by the Drugs Controller General of India and by USFDA. It has been passed on to Industry and is available to Public. The second Vaccine was devised for Birth Control. It is hCG beta linked to LTB, as carrier. It is engineered as a recombinant vaccine, so as to be amenable to industrial production. The vaccine has received approval of the National Review Committee on Genetic Manipulation. It has also received approval of the Drugs Controller General of India for going to clinical trials for prevention of unwanted children. In previous years, Phase II trials on an anti-hCG Vaccine had shown high efficacy of the Vaccine to prevent pregnancy without derangement of ovulation and menstrual regularity.
E-mail: [email protected]